Expression profile of Toll‑like receptors in human breast cancer

Shi,Shuxun; Xu,Cong; Fang,Xiaonan; Zhang,Yonghuan; Li,Hua; Wen,Wujun; Yang,Guiwen

doi:10.3892/mmr.2019.10853

Expression profile of Toll‑like receptors in human breast cancer

Authors:
- Shuxun Shi
- Cong Xu
- Xiaonan Fang
- Yonghuan Zhang
- Hua Li
- Wujun Wen
- Guiwen Yang
View Affiliations

Affiliations: Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Sciences, Shandong Normal University, Jinan, Shandong 250014, P.R. China
Published online on: November 26, 2019 https://doi.org/10.3892/mmr.2019.10853
Pages: 786-794
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll‑like receptors (TLRs) are the most widely studied pattern recognition receptors. Mounting evidence suggests an important association between TLRs and the occurrence and development of breast cancer. Thus, targeting these receptors may be a potential strategy for breast cancer treatment. The current study analyzed the data of 1,215 patients with breast cancer obtained from The Cancer Genome Atlas (TCGA) database. It was observed that, in addition to TLR6, TLR7 and TLR8, the expression of the remaining TLRs in breast cancer tissues was lower than that in normal tissues. In addition, TLR3 and TLR9 displayed significantly different expression levels in ER‑/PR‑negative breast cancer compared with the control tissues, while TLR5 expression was significantly reduced in HER2‑enriched breast cancer. Furthermore, TLR10 exhibited lower expression levels in advanced stages of the disease as compared with that observed in earlier stages. Survival analysis revealed that the expression of TLR4 and TLR7 had a significant impact on survival, and higher expression levels suggested worse prognosis. Finally, the expression levels of TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 were correlated with those of the inflammatory cytokines interleukin‑1β and tumor necrosis factor‑α, while the expression levels of TLR3, TLR7, TLR8 and TLR9 were correlated with those of interferon‑β and C‑X‑C motif chemokine ligand 10. Taken together, the current study results suggest that TLR expression may serve as a biomarker of cancer pathogenesis and progression, and may provide new insights for the treatment of breast cancer through the regulation and targeting of TLRs.

View Figures

View References

1	Mifsud EJ, Tan AC and Jackson DC: TLR Agonists as modulators of the innate immune response and their potential as agents against infectious disease. Front Immunol. 5:792014. View Article : Google Scholar : PubMed/NCBI
2	Brubaker SW, Bonham KS, Zanoni I and Kagan JC: Innate immune pattern recognition: A cell biological perspective. Annu Rev Immunol. 33:257–290. 2015. View Article : Google Scholar : PubMed/NCBI
3	Palm E, Demirel I, Bengtsson T and Khalaf H: The role of Toll-like and protease-activated receptors in the expression of cytokines by gingival fibroblasts stimulated with the periodontal pathogen Porphyromonas gingivalis. Cytokine. 76:424–432. 2015. View Article : Google Scholar : PubMed/NCBI
4	Johnston DG and Corr SC: Toll-like receptor signalling and the control of intestinal barrier function. Methods Mol Biol. 1390:287–300. 2016. View Article : Google Scholar : PubMed/NCBI
5	Rakoff-Nahoum S and Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer. 9:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
6	Yu L and Chen S: Toll-like receptors expressed in tumor cells: Targets for therapy. Cancer Immunol Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI
7	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
8	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
9	Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J and Shi B: Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 5:2929–2243. 2015.PubMed/NCBI
10	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
11	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
12	Yadav BS, Chanana P and Jhamb S: Biomarkers in triple negative breast cancer: A review. World J Clin Oncol. 6:252–263. 2015. View Article : Google Scholar : PubMed/NCBI
13	Xie W, Wang Y, Huang Y, Yang H, Wang J and Hu Z: Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 379:1027–1032. 2009. View Article : Google Scholar : PubMed/NCBI
14	Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, et al: TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71:1607–1614. 2011. View Article : Google Scholar : PubMed/NCBI
15	Haricharan S and Brown P: TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci USA. 112:E3216–E3225. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ehsan N, Murad S, Ashiq T, Mansoor MU, Gul S, Khalid S and Younas M: Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol. 34:1053–1059. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cai Z, Sanchez A, Shi Z, Zhang T, Liu M and Zhang D: Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71:2466–2475. 2011. View Article : Google Scholar : PubMed/NCBI
18	Shuang C, Weiguang Y, Zhenkun F, Yike H, Jiankun Y, Jing X, Xinghan L, Yue L and Dalin L: Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility. Oncotarget. 8:88622–88629. 2017. View Article : Google Scholar : PubMed/NCBI
19	Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, et al: Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
20	Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, Young HA, Trinchieri G and Wink DA: Molecular pathways: Toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity. Clin Cancer Res. 19:1340–1346. 2013. View Article : Google Scholar : PubMed/NCBI
22	Sato Y, Goto Y, Narita N and Hoon DS: Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2 (Suppl 1):S205–S214. 2009. View Article : Google Scholar
23	Wang X, Smith C and Yin H: Targeting Toll-like receptors with small molecule agents. Chem Soc Rev. 42:4859–4866. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kidd LC, Rogers EN, Yeyeodu ST, Jones DZ and Kimbro KS: Contribution of Toll-like receptor signaling pathways to breast tumorigenesis and treatment. Breast Cancer (Dove Med Press). 5:43–51. 2013.PubMed/NCBI
25	Green TL, Santos MF, Ejaeidi AA, Craft BS, Lewis RE and Cruse JM: Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol. 97:44–48. 2014. View Article : Google Scholar : PubMed/NCBI
26	Amarante MK, de Oliveira KB, Guembarovski RL, da Silva do Amaral Herrera AC, Guembarovski AL, Sobrinho WJ, Voltarelli JC and Watanabe MA: Toll-like receptor 3: implications for proinflammatory microenvironment in human breast cancer. Mol Biol Rep. 39:11087–11092. 2012. View Article : Google Scholar : PubMed/NCBI
27	González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JM and Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 10:6652010. View Article : Google Scholar : PubMed/NCBI
28	Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H and Zhu X: Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 29:922010. View Article : Google Scholar : PubMed/NCBI
29	Yeyeodu ST, Kidd LR, Oprea-Ilies GM, Burns BG, Vancleave TT, Shim JY and Kimbro KS: IRAK4 and TLR3 sequence variants may alter breast cancer risk among African-American women. Front Immunol. 4:3382013. View Article : Google Scholar : PubMed/NCBI
30	Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW and Selander KS: Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun. 1:59–68. 2009. View Article : Google Scholar : PubMed/NCBI
31	Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, Jirström K and Leandersson K: Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res. 17:1302015. View Article : Google Scholar : PubMed/NCBI
32	Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, Van Denend N, Larson ER, Chang A, Tufvesson H and Disis ML: Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol. 184:5360–5367. 2010. View Article : Google Scholar : PubMed/NCBI
33	Bhatelia K, Singh K and Singh R: TLRs: Linking inflammation and breast cancer. Cell Signal. 26:2350–2357. 2014. View Article : Google Scholar : PubMed/NCBI
34	Motshwene PG, Moncrieffe MC, Grossmann JG, Kao C, Ayaluru M, Sandercock AM, Robinson CV, Latz E and Gay NJ: An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem. 284:25404–25411. 2009. View Article : Google Scholar : PubMed/NCBI
35	Lin SC, Lo YC and Wu H: Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 465:885–890. 2010. View Article : Google Scholar : PubMed/NCBI
36	Gay NJ, Gangloff M and O'Neill LA: What the Myddosome structure tells us about the initiation of innate immunity. Trends Immunol. 32:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
37	Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al: Breast cancer prognostic classification in the molecular era: The role of histological grade. Breast Cancer Res. 12:2072010. View Article : Google Scholar : PubMed/NCBI